Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Biotron ( (AU:BIT) ) is now available.
Biotron reported new preclinical data showing its lead hepatitis B candidate, BIT-HBV001, demonstrated strong antiviral activity against hepatitis delta virus in co-infected cell models, significantly reducing markers of HDV infection. The finding broadens the drug’s potential to treat hard-to-treat HBV/HDV co-infected patients, a population at high risk of rapid progression to severe liver disease and with limited existing therapeutic options.
The company also confirmed that its acquisition of Sedarex Limited is now fully integrated and that it is advancing regulatory strategy for SedRx, Sedarex’s next-generation general anaesthetic. Biotron is preparing a submission to the European Medicines Agency for scientific advice and is concurrently exploring accelerated approval routes in the U.S., developments that could diversify its portfolio and reshape its future revenue mix if the programs advance successfully.
The most recent analyst rating on (AU:BIT) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Biotron stock, see the AU:BIT Stock Forecast page.
More about Biotron
Biotron Limited is an Australian biotechnology company listed on the ASX that develops antiviral therapies and, through its Sedarex acquisition, next-generation general anaesthetics. Its pipeline targets serious infectious diseases such as hepatitis B and associated co-infections, while also pursuing regulatory pathways for innovative hospital-use medicines in major markets including Europe and the U.S.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.75M
For an in-depth examination of BIT stock, go to TipRanks’ Overview page.